10 employees
Bioenvision engages in the acquisition, development and marketing of compounds and technologies primarily for the treatment of cancer.
1996
$7.4M
from 2 investors over 2 rounds
Bioenvision raised $7.4M on April 30, 2007
Investors: Aisling Capital and Perseus